ADHD Medication Not Linked to Higher Self-Harm Risk

ADHD medication was not linked to a higher risk of self-harm in a large study of people with attention deficit hyperactivity disorder, according to a report in The Pharmaceutical Journal. The researchers found that risk was highest in the period before treatment started, then fell once people began taking ADHD medication.

The finding speaks to a worry that many patients and families raise when treatment is first discussed: whether starting ADHD medication could itself raise the risk of self-harm. In this study, the pattern ran the other way. Risk peaked before the first prescription, eased in the opening months of treatment, and eased further with longer use. The authors said the results support timely diagnosis and treatment, alongside continued monitoring of risk before and during treatment, rather than delaying treatment over safety concerns.

What the researchers tracked

The study, published in BMJ Mental Health in September 2026, drew on medical records from people with ADHD who had been prescribed medication between 2001 and 2020. The records covered patients in the UK, Hong Kong, New Zealand, South Korea and Taiwan. In total, the analysis included 461,024 people. The team compared self-harm incidents across three windows: the months before a person started ADHD medication, the opening months of use, and the period that followed.

Across the sites studied, the rate of self-harm was highest before treatment began. It dropped after people started ADHD medication and dropped again in the later treatment period. The researchers noted that earlier studies had produced mixed results, with some pointing to a higher risk shortly after treatment started and others pointing to a lower risk. A study this large, spanning several health systems, gives a clearer picture than any single-country sample could, though the authors were careful about what the design can and cannot show.

Why the timing matters

The period before diagnosis and treatment is often when symptoms are at their most disruptive. School, work, relationships and daily routines can all strain under untreated ADHD, and support may not yet be in place. Lead author Adrienne Chan, a lecturer in pharmacoepidemiology at Aston University, said many people are already at their highest risk before treatment begins, and that recognising that vulnerable period could allow support to arrive earlier, when it may make the greatest difference.

That reading was echoed by Henry Shelford, chief executive of ADHD UK, who said it was unsurprising that people were often struggling most before a diagnosis, since that struggle is usually what prompts a request for help. He argued that the system should diagnose and support people proactively instead of requiring a crisis before help arrives, and he pointed to the wider evidence that ADHD medication can lower risks around suicide, addiction and harm from increased risk-taking.

For families weighing a new prescription, the practical message is narrower than a blanket reassurance. ADHD medication works alongside monitoring, follow-up appointments, and support at home and school. The study authors stressed ongoing monitoring of self-harm risk before and during treatment. A prescriber who knows that risk tends to peak before treatment can watch that window closely and keep checking in after the first prescription, rather than treating the start of treatment as the moment of greatest danger.

What the findings do not settle

An observational study of medical records can show how risk changes over time, but it cannot prove that ADHD medication caused the fall. People who start treatment also gain contact with clinicians, a diagnosis that explains longstanding difficulties, and often other forms of support, and any of those changes could contribute to the pattern. The study also grouped together different medications and different health systems, so it does not answer whether one particular drug carries a different risk profile from another.

Readers should also note the limits of record-based research. Self-harm that never reaches a clinician or a hospital record will not appear in the data, and recording practices differ between countries. Those limits do not erase the headline result, but they are a reason to read it as evidence about timing and risk across a population, not as a prediction for any one person. Anyone who is worried about self-harm, whether they take ADHD medication or not, should seek help promptly from a clinician, a crisis line, or emergency services in their country.

The broader context is a long-running debate about ADHD treatment, in which fears about medication safety have sometimes slowed diagnosis and prescribing. This study adds a large, multi-country data point to that debate, and its central observation is about sequence: the danger period identified here came before treatment, not after it. Related GenZ NewZ coverage has looked at how anxiety-linked brain circuits appear in early adolescence and at how a sense of belonging tracks with teen mental health, two reminders that early support, in whatever form it takes, tends to matter more than waiting for a crisis.